Muscle pain with taking statin

Slides:



Advertisements
Similar presentations
Prevention of Contrast-Induced Nephropathy (CIN) Sepehr Khashaei, MD Assistant professor Department of Internal Medicine.
Advertisements

© 2006 National Lipid Association Statin Safety: Key Conclusions and Recommendations of the NLA.
Clinical question: When do you get statin induced myopathy?
AA-7-1 René Belder, MD Executive Director Clinical Development and Life Cycle Management Cardiovascular / Metabolics 7asdf.
FATS4 Linking cases to the guideline Jane S Skinner Consultant Community Cardiologist.
Slide Source: Lipids Online Slide Library Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.
STATINS AGAIN. Atorvastatin Off patent Atorvastatin 40 = £36 PA Simvastatin 40 = £14 PA Atorvastatin 80 = £72 PA Simvastatin 80 = £24 PA.
Rhabdomyolysis W. Rose. Rhabdomyolysis W. Rose 2015 Condition in which muscle cells die and release intracellular contents into the systemic circulation.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
Drugs in the Body (1) Recurrence Relations A patient is given an initial dose of 50mg of a drug. Each hour the patient is given a 20mg tablet of the.
Respiratory CONNECT meeting Dr Julius Cairn. Risk stratification in PE Clinical parameters – shock, JVP, S3 Imaging – CTPA, echo Biomarkers – Troponin,
Statin Induce Myotoxicity
David J. Graham et al. JAMA, 2004; 292: 2585 Description of Inception Cohorts for Patients Using Statin and Fibrate Drug Therapy.
Modern cardiology support for the acute oncology patient Chris Plummer Cardiology, Freeman Hospital.
Endocrinologic & Metabolic Drugs Advisory Committee Meeting
Safety update Anthony Ormerod. Why is safety important? Clinical trial / European directive MHRA / governance Severe disease Patients have large burden.
B-1 Pravastatin-Aspirin Combination René Belder, M.D. Executive Director Clinical Design and Evaluation, Metabolics Pharmaceutical Research Institute Bristol-Myers.
The Hyperlipidaemias What are they and how to treat Dr John O’Donnell Consultant Clinical Biochemist Borders General Hospital.
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Scott W. Rypkema, M.D.
Lipitor Alternative Drugs Cheap Atorvastatin Online lipitor patent status atorvastatin calcium forms lipitor prescriptions lipitor old age lipitor dosage.
Double-blind, randomized trial in 4,162 patients with Acute Coronary Syndrome
Angela Aziz Donnelly April 5, 2016
CARLY LAURAINE KEENE STATE DIETETIC INTERN SAMARITAN MEDICAL CENTER Final Case Study Presentation.
Statins induced myopathy
Addressing the Challenges in Primary and Secondary Stroke Prevention
Statin Myopathy (AHA/ACC/NHLBI)
3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.
Pravastatin in Elderly Individuals at Risk of Vascular Disease
Primary end point of the ANZICS low-dose dopamine trial
Diabetic Dyslipidemia in Practice
Statin Selection in the Elderly
Optimizing Statin Therapy
Acute Heart Failure.
Long-Term Treatment of VTE: Case Studies
Drug induced myopathy Edition
Challenging Statin Intolerance: Back to Basics
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
Patient 1: 53-Year-Old Man With CVD Risk Factors
Patients aged 85yrs and over
PCP Perspectives Clinical Considerations in Hyperkalemia
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
Understanding Statin Metabolism
Oral Anticoagulants in AFa,b A Brief History.
Beyond Statin Therapy.
Statins and New-Onset Diabetes REAL Updates and Clinical Implications
Diabetes Increases Risk of CVD
Assessing the State of Statin Therapy
A Pharmacist's Guide to PCSK9 Inhibitors:
What’s New in Hypothyroidism?
Statins and Glucose Metabolism: Are All Agents Alike?
Learning Objectives Classification of VTE Goals of VTE Treatment.
Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors
Oral Anticoagulation in AF
Pharmacovigilance workshop
A: Kaplan-Meier estimate of time to first LLA
Residual CV Risk in Patients With Dyslipidemia and Stable CAD
Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?
Long-Term Treatment of VTE: Case Studies
When Is Intrathecal Drug Delivery Appropriate?
Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.
Periprocedural Management of Patients on Anticoagulation
Statins, Obesity, and Hyperlipidemia
Princess Margaret Hospital Dr. Winsome Lo
When Is Intrathecal Drug Delivery Appropriate?
Major classes of drugs to reduce lipids
Chest Pain Choice Trial design: Patients presenting to the ED with low risk chest pain were randomized to either use of a tailored decision aid or routine.
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
Lipids, the Heart, and the Kidney
Section 6: Update on lipid treatment guidelines
Presentation transcript:

Muscle pain with taking statin Stop statin and check CK, allow CK to return to baseline No clinical rhabdo and CK < 3x normal Clinical rhabdo with CK >= 3x normal If obvious reversible cause,* correct and if high CVD risk, consider careful re-challenge or change to pravastatin Correct reversible causes* and either 1) re-challenge or 2) change to pravastatin Success *reversible causes: drug interaction, hypothyroid, acute renal failure, biliary obstruction Recurrence Success Consider trial of every other day dosing Recurrence Stop statin, consider alternate agent in high risk patients